Evidence map›Paper›PMID 41706242›Full record

ReviewCurrent neurology and neuroscience reports2026

Advanced Therapeutics in Parkinson's Disease: What's New?

Mariana H G Monje, Jessica A Karl, Christa S Cooper, Jacob Yomtoob, Juan Deliz, Lucy A Morse, Neil Shetty, Leonard Verhagen Metman

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mariana H G MonjeKen and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Lavin Family Pavilion, 259 E Erie St suite 1900, Chicago, IL, 60611, USA.ORCID http://orcid.org/0000-0002-0730-4061
Jessica A KarlKen and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Lavin Family Pavilion, 259 E Erie St suite 1900, Chicago, IL, 60611, USA.
Christa S CooperKen and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Lavin Family Pavilion, 259 E Erie St suite 1900, Chicago, IL, 60611, USA.
Jacob YomtoobKen and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Lavin Family Pavilion, 259 E Erie St suite 1900, Chicago, IL, 60611, USA.
Juan DelizKen and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Lavin Family Pavilion, 259 E Erie St suite 1900, Chicago, IL, 60611, USA.
Lucy A MorseKen and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Lavin Family Pavilion, 259 E Erie St suite 1900, Chicago, IL, 60611, USA.
Neil ShettyKen and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Lavin Family Pavilion, 259 E Erie St suite 1900, Chicago, IL, 60611, USA.
Leonard Verhagen MetmanKen and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Lavin Family Pavilion, 259 E Erie St suite 1900, Chicago, IL, 60611, USA. leonard.verhagenmetman@northwestern.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewTo provide a concise, clinically oriented update on advanced therapies for Parkinson’s disease. RECENT

findingsSubcutaneous infusion of foscarbidopa/foslevodopa and apomorphine reduce OFF time and improve “good ON time”, though infusion site reactions remain of some concern. Image-guided programming may shorten programming time while matching motor outcomes; while adaptive/closed-loop deep brain stimulation using local field potential signals may improve symptoms and quality of life with a lower energy use. Remote programming accelerates clinical benefit and expands access. Approved magnetic resonance guided high intensity focused ultrasound targets now include the ventralis intermediate nucleus of the thalamus, the globus pallidus pars interna and, recently, the pallidothalamic tract; while research investigates the subthalamic nucleus, each target with distinct benefits and adverse event profiles. Early studies using magnetic resonance guided low intensity focused ultrasound show safe, transient blood brain barrier opening. First-in-human stem cells-derived dopaminergic grafts show safety and graft functioning. The advanced therapeutic landscape for Parkinson’s disease has evolved through innovations in established and novel therapies. Future priorities for the field include standardized biomarkers and protocols for adaptive deep brain stimulation, long-term evaluation of high intensity focused ultrasound outcomes, and rigorously controlled trials of low intensity focused ultrasound and cell-based therapies designed to assess disease-modifying potential.

Indexed as

Antiparkinson AgentsDeep Brain StimulationParkinson DiseaseAnimalsHumansAntiparkinson AgentsCell therapyDeep brain stimulationHigh-intensity focused ultrasound ablationInfusionsInterventional magnetic resonance imaging

Identifiers

PMID41706242
PMCPMC12916957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.